EXTON, Pa., March 22, 2021 /PRNewswire/ — Glomerular ailments, together with IgA nephropathy (IgAN), focal segmental glomerulosclerosis (FSGS), and Alport Syndrome, amongst others, collectively quantity to the third main explanation for power kidney illness (CKD) and account for about 10% of sufferers on dialysis.1 Sufferers affected by these progressive, and sometimes idiopathic, ailments have few (if any) dependable and efficient therapy choices – posing important challenges to treating nephrologists.
Spherix World Insights has been maintaining a pulse on the nephrology group since 2015, and as pharmaceutical firms have prioritized a few of the uncommon glomerular ailments for product improvement, there was a parallel dramatic shift in nephrologists’ curiosity in these issues. Actually, greater than one-half of nephrologists chosen glomerular ailments as their main space of curiosity in nephrology in 2020, rating it primary throughout greater than ten totally different renal issues.
To higher perceive referral patterns and precisely how sufferers current to nephrologists, together with affected person sorts, present therapy paradigms, and unmet wants, Spherix commissioned a number of new main analysis research from December 2020 by way of late February 2021. This analysis, obtainable by way of their RealWorld Dynamix™ service choices, consists of enter from a whole lot of physicians on their perceptions and experiences in treating IgAN, FSGS, and Alport Syndrome, and consists of chart audits on 468 IgAN sufferers, 493 FSGS sufferers, and 151 Alport Syndrome sufferers.
The reviews define the challenges physicians face in figuring out how aggressively to deal with sufferers and emphasize lots of the frustrations they’ve with present therapy paradigms, significantly with using steroids. To assist biopharmaceutical firms higher perceive doctor enthusiasm with merchandise in improvement and to scope potential future use of those brokers, nephrologists have been pulsed on familiarity with main pipeline candidates, after which requested the probability of prescribing merchandise for sufferers included within the audit.
This information permits for firms to dig additional into affected person sorts and potential market alternatives. Merchandise evaluated embrace: bardoxolone methyl (Reata) and lademirsen (Sanofi-Genzyme) in Alport Syndrome; sparsentan (Travere), bleselumab (Astellas/Kyowa Kirin), VAR 200 (Zyversa) and VX-147 (Vertex) in FSGS; and Nefecon (Calliditas), iptacopan (Novartis), narsoplimab (Omeros), VIS649 (Otsuka and Visterra), atrasentan and BION-1301 (Chinook), and atacicept (Vera Therapeutics) in IgAN.
About RealWorld Dynamix™
RealWorld Dynamix™ is an unbiased, data-driven service unveiling actual affected person administration patterns by way of rigorous evaluation of large-scale affected person chart audits. Insights reveal the “why” behind therapy choices, embrace 12 months over 12 months trending to quantify key points of market evolution, and combine specialists’ attitudinal & demographic information to focus on variations between acknowledged and precise therapy patterns.
RealWorld Dynamix™: IgA Nephropathy (US), 468 affected person charts from n=188 nephrologists
RealWorld Dynamix™: Focal Segmental Glomerulosclerosis (US), 493 FSGS affected person charts from n=188 nephrologists
RealWorld Dynamix™: Alport Syndrome (US), 151 affected person charts from n=102 nephrologists
About Spherix World Insights
Spherix World Insights is a hyper-focused market intelligence agency that leverages our personal unbiased information and experience to offer strategic steerage, so biopharma stakeholders make choices with confidence. We specialise in choose immunology, nephrology, and neurology markets.
All firm, model or product names on this doc are logos of their respective holders.
SOURCE Spherix World Insights